Boyd Eugene Haley
|Alma mater||Franklin College, University of Idaho, Washington State University|
|Known for||Photoaffinity labeling|
|Institutions||University of Wyoming, University of Kentucky|
|Thesis||Gamma-fluoro-adenosinetriphosphate: I. Synthesis and properties; II. Interaction with myosin, heavy meromyosin, and fumarase. (1971)|
Education and career
A native of Greensburg, Indiana, Haley graduated from its New Point High School in 1959. Four years later, he received a bachelor's degree from Franklin College in Franklin, Indiana, and then entered a teaching fellowship at Howard University. Thereafter, he served as a U.S. Army medic a few years.
In 1967, Haley obtained an M.S. degree from the University of Idaho. He then entered a doctoral program at Washington State University, where he worked "to make chemical modifications on ATP to try to identify how and exactly where ATP binds to cause muscle movement." In 1971, WSU granted him his Ph.D. degree in chemistry-biochemistry.
For three years, Haley served as a postdoctoral scholar at Yale University. From 1974 to 1985, he was a professor at the University of Wyoming. hereafter, he was appointed professor of medicinal chemistry at the University of Kentucky, whose chemistry department he became chairperson of in 1997. He is now professor emeritus.
In 1992, Haley and a colleague, upon examining cerebrospinal fluid, reported levels of glutamine synthetase considerably higher in cases of Alzheimer's disease than in a control group, and suggested that this could be a biomarker to aid diagnosis.
In 2005, Haley reproduced findings of gold salt removing mercury from molecules, and inferred support for the possibility of gold salts removing mercury from biological proteins. Yet Haley noted that the gold salts could themselves be toxic, and called for the extreme caution before applying gold salts in medical treatment.
Haley argues that mercury exposure via dental amalgams and vaccinations may cause neurological impairments and diseases, such as autism and Alzheimer's disease. The United States Public Health Service and the American Dental Association reject these claims.
Haley has appeared in court as an expert witness against vaccine manufacturers, stating his belief that thimerosal causes autism, but his testimony has not been accepted. In 2008 a judge ruled that his "lack of expertise in genetics, epidemiology, and child neurology make it impossible for him to supply the necessary factual basis to support his testimony".
Haley is the founder of CTI Science, a Lexington, Kentucky-based biotechnology firm. CTI marketed a product, OSR#1, for human consumption; it was described as an "antioxidant" dietary supplement that is a powerful chelator from a family originally developed to remove heavy metals from soil and acid mine drainage. In June 2008, an FDA toxicologist questioned "on what basis the product could be expected to be safe and could be considered a dietary ingredient", but CTI Science and Haley had not responded as of January 2010. The testing was described as incomplete and indicating toxicity. On June 17, 2010, the FDA sent a warning letter noting five potential violations, expressing concern over the testing, and requiring a response in 15 days. Although Haley wrote an op-ed for the Lexington Herald-Leader, the FDA did not receive a formal response, and OSR#1 was withdrawn from the market.
- "James "Jim" Haley". Muskogee Phoenix. 4 September 2007. Retrieved 29 August 2013.
- "Curriculum Vitae" (PDF). Food and Drug Administration. Retrieved 6 August 2013.
- "Boyd Eugene Haley". Greensburg Daily News. 13 June 1963.
- Worley, Jeff (25 September 2003). "Boyd Haley: Tagging toxins for better health". University of Kentucky. Archived from the original on 13 November 2014. Retrieved 7 October 2013.
- "Adjunct & emeritus faculty", College of Arts & Sciences—Chemistry wepbage, University of Kentucky website, accessed 13 Jun 2017.
- Gunnersen D, Haley B (December 1992). "Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: A potential diagnostic biochemical marker". Proc. Natl. Acad. Sci. U.S.A. 89 (24): 11949–53. doi:10.1073/pnas.89.24.11949. PMC 50675. PMID 1361232.
- "A possible Alzheimer marker is found". The New York Times. 15 December 1992. Retrieved 12 February 2014.
- Olmsted, Dan (2005-12-30). "The Age of Autism: Gold standards". United Press International. Archived from the original on 20 March 2008. Retrieved 2008-01-04.
- Rockmarch, Andrea. (April 2004). "Toxic Tipping Point", Mother Jones. Retrieved August 26, 2018.
- "Questions and Answers on Dental Amalgam". Food and Drug Administration. 2006-10-30. Archived from the original on 2007-10-19. Retrieved 2008-01-04.
- "ADA Statement on Dental Amalgam". American Dental Association. 2007-04-06. Archived from the original on 2007-10-11. Retrieved 2008-01-04.
- Offit PA (2010). "Behind the Mercury Curtain". Autism's False Prophets: Bad Science, Risky Medicine, and the Search for a Cure. Columbia University Press. pp. 132–133. ISBN 978-0-231-14637-1.
- "OSR#1: Industrial chemical or autism treatment?", Chicago Tribune, January 17, 2010
- FDA letters and documents
- "FDA warns maker of autism supplement". UPI. June 24, 2010. Retrieved September 12, 2011.
- Warning letter CIN-10-107927-14 from US FDA, June 17, 2010
- Tsouderos, Trine (June 23, 2010). "FDA warns maker of product used as alternative autism treatment". Chicago Tribune. ISSN 1085-6706. Retrieved September 12, 2011.
- Haley, Boyd (June 26, 2010). "Dietary supplement safe for right use". Lexington Herald-Leader. ISSN 0745-4260. Retrieved September 12, 2011.
- Tsouderos, Trine (July 12, 2010). "Supplement seller says FDA may be 'confused'". Chicago Tribune. ISSN 1085-6706. Retrieved September 12, 2011.
- Tsouderos, Trine (July 26, 2010). "Controversial supplement to come off shelves". Chicago Tribune. ISSN 1085-6706. Retrieved September 12, 2011.